Immunotherapies should be combined with TKIs

Immunotherapies should be combined with TKIs

obr

1 year
35 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ghassan Abou-Alfa, MD, MBA, explains how immunotherapies should be combined with TKIs at Annual Meeting 2018.
Up Next Autoplay
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
2 Views
Mount Sinai Health System 1 week
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
20 Views
Cancer-News 1 month
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
13 Views
Cancer-News 2 months
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
19 Views
Cancer-News 2 months
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
12 Views
Cancer-News 2 months
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
118 Views
Annual-Meeting 5 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
26 Views
Annual-Meeting 5 months
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Category: General
48 Views
Annual-Meeting 5 months
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Category: General
76 Views
Annual-Meeting 5 months
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
Category: General
301 Views
Annual-Meeting 5 months